{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:46:27Z","timestamp":1789685187767,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study investigates the impact of semaglutide on obstructive sleep apnea (OSA) risk and clinical outcomes in individuals with obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using the TriNetX platform, which includes electronic health records from approximately 150 million patients across 149 healthcare organizations. Two cohorts were analyzed: (1) individuals with obesity to evaluate the incidence of new-onset OSA and (2) individuals with OSA and obesity to assess clinical outcomes. Propensity score matching was applied to balance baseline characteristics between semaglutide users and control groups. Primary outcomes included new-onset OSA incidence (obesity cohort) and a composite endpoint of all-cause mortality, major adverse cardiovascular events (MACEs), and major adverse kidney events (MAKEs) (OSA with obesity cohort).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the obesity cohort (n\u2009=\u2009191\u2009273 in each group), semaglutide use was significantly associated with a reduced the risk of new-onset OSA (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.60-0.63; P\u2009&amp;lt;\u2009.0001). Stratified analyses confirmed consistent benefits across subgroups. In the OSA with obesity cohort (n\u2009=\u200940\u2009123 in each group), semaglutide use was associated with lower risk of adverse composite outcomes (HR, 0.72; 95% CI, 0.66-0.78; P\u2009&amp;lt;\u2009.0001), as well as reductions in all-cause mortality (HR, 0.37; 95% CI, 0.31-0.45), MACE (HR, 0.72; 95% CI, 0.65-0.79), and MAKE (HR, 0.54; 95% CI, 0.48-0.60). Sensitivity analyses confirmed robustness against unmeasured confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide was associated with a significant reduction in OSA risk among individuals with obesity and improved clinical outcomes in those with comorbid obesity and OSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/annalsats\/aaoaf070","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:02:25Z","timestamp":1769158945000},"page":"584-596","source":"Crossref","is-referenced-by-count":2,"title":["Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity"],"prefix":"10.1093","volume":"23","author":[{"given":"Jheng-Yan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Nutrition, Chi Mei Medical Center , Tainan,","place":["Taiwan"]},{"name":"Department of Public Health, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center , Chiali, Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsuan","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-3923","authenticated-orcid":false,"given":"Ya-Wen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hsiang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Medicine, National Cheng Kung University , Tainan,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center , Tainan,","place":["Taiwan"]},{"name":"School of Medicine, College of Medicine, National Sun Yat-sen University , Kaohsiung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026033111265335500_aaoaf070-B1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"","year":"2025","journal-title":"Lancet"},{"key":"2026033111265335500_aaoaf070-B2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"","year":"2025","journal-title":"Lancet"},{"key":"2026033111265335500_aaoaf070-B3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026033111265335500_aaoaf070-B4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1513\/pats.200708-137MG","article-title":"Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches","volume":"5","author":"Schwartz","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"2026033111265335500_aaoaf070-B5","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1097\/00005768-199911001-00019","article-title":"Comorbidities of overweight and obesity: current evidence and research issues","volume":"31","author":"Pi-Sunyer","year":"1999","journal-title":"Med Sci Sports Exerc"},{"key":"2026033111265335500_aaoaf070-B6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s42255-024-01113-9","article-title":"GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management","volume":"6","author":"Holst","year":"2024","journal-title":"Nat Metab"},{"key":"2026033111265335500_aaoaf070-B7","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1111\/apt.17848","article-title":"Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases","volume":"59 Suppl 1","author":"Giannakogeorgou","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"2026033111265335500_aaoaf070-B8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","article-title":"Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients","volume":"20","author":"Saraiva","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026033111265335500_aaoaf070-B9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"2026033111265335500_aaoaf070-B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026033111265335500_aaoaf070-B11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"2026033111265335500_aaoaf070-B12","doi-asserted-by":"publisher","first-page":"103942","DOI":"10.1016\/j.ebiom.2022.103942","article-title":"Hypoxia and chronic kidney disease","volume":"77","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"2026033111265335500_aaoaf070-B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fphys.2012.00029","article-title":"Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity","volume":"3","author":"Vink","year":"2012","journal-title":"Front Physiol"},{"key":"2026033111265335500_aaoaf070-B14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1681\/ASN.2020121723","article-title":"Activation of sympathetic signaling in macrophages blocks systemic inflammation and protects against renal ischemia-reperfusion injury","volume":"32","author":"Hasegawa","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026033111265335500_aaoaf070-B15","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1111\/dom.16353","article-title":"Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: a multi-institutional propensity score-matched study","volume":"27","author":"Wu","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026033111265335500_aaoaf070-B16","doi-asserted-by":"publisher","first-page":"106984","DOI":"10.1016\/j.ijantimicag.2023.106984","article-title":"Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19","volume":"62","author":"Wu","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026033111265335500_aaoaf070-B17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP1 receptor agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr"},{"key":"2026033111265335500_aaoaf070-B18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"2026033111265335500_aaoaf070-B19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s12072-025-10857-9","article-title":"Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study","volume":"19","author":"Wu","year":"2025","journal-title":"Hepatol Int"},{"key":"2026033111265335500_aaoaf070-B20","doi-asserted-by":"publisher","first-page":"112294","DOI":"10.1016\/j.diabres.2025.112294","article-title":"Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: a multi-institutional propensity score matched study","volume":"226","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026033111265335500_aaoaf070-B21","doi-asserted-by":"publisher","first-page":"112083","DOI":"10.1016\/j.diabres.2025.112083","article-title":"Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients","volume":"222","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"2026033111265335500_aaoaf070-B22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/27697061.2025.2461215","article-title":"Clinical outcomes in diabetic patients with zinc deficiency: a multi-institutional population-based study","volume":"44","author":"Wu","year":"2025","journal-title":"J Am Nutr Assoc"},{"key":"2026033111265335500_aaoaf070-B23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/NT.0000000000000092","article-title":"Body mass index: obesity, BMI, and health: a critical review","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr Today"},{"key":"2026033111265335500_aaoaf070-B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4321\/s1886-36552014000400007","article-title":"Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy","volume":"12","author":"Singh","year":"2014","journal-title":"Pharm Pract (Granada)"},{"key":"2026033111265335500_aaoaf070-B25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1198\/000313001317097960","article-title":"On judging the significance of differences by examining the overlap between confidence intervals","volume":"55","author":"Schenker","year":"2001","journal-title":"Am Stat"},{"key":"2026033111265335500_aaoaf070-B26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026033111265335500_aaoaf070-B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026033111265335500_aaoaf070-B28","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","article-title":"Negative control outcomes: a tool to detect bias in randomized trials","volume":"316","author":"Arnold","year":"2016","journal-title":"JAMA"},{"key":"2026033111265335500_aaoaf070-B29","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.mayocp.2018.04.026","article-title":"Bidirectional relationships between weight change and sleep apnea in a behavioral weight loss intervention","volume":"93","author":"Kline","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2026033111265335500_aaoaf070-B30","doi-asserted-by":"publisher","first-page":"104014","DOI":"10.1016\/j.numecd.2025.104014","article-title":"Obesity and sleep disorders: a bidirectional relationship","volume":"35","author":"Figorilli","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026033111265335500_aaoaf070-B31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.smrv.2012.05.002","article-title":"The reciprocal interaction between obesity and obstructive sleep apnoea","volume":"17","author":"Ong","year":"2013","journal-title":"Sleep Med Rev"},{"key":"2026033111265335500_aaoaf070-B32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/resp.13838","article-title":"Global burden of sleep-disordered breathing and its implications","volume":"25","author":"Lyons","year":"2020","journal-title":"Respirology"},{"key":"2026033111265335500_aaoaf070-B33","doi-asserted-by":"publisher","first-page":"210200","DOI":"10.1183\/16000617.0200-2021","article-title":"European respiratory society guideline on non-CPAP therapies for obstructive sleep apnoea","volume":"30","author":"Randerath","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2026033111265335500_aaoaf070-B34","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026033111265335500_aaoaf070-B35","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"2026033111265335500_aaoaf070-B36","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","journal-title":"Sleep Breath"},{"key":"2026033111265335500_aaoaf070-B37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026033111265335500_aaoaf070-B38","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"2026033111265335500_aaoaf070-B39","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026033111265335500_aaoaf070-B40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoaf070\/66511412\/aaoaf070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/4\/584\/66511412\/aaoaf070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/23\/4\/584\/66511412\/aaoaf070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:26:57Z","timestamp":1774970817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/23\/4\/584\/8435340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,23]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/annalsats\/aaoaf070","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,23]]}}}